SWOG S2013

Clinical Trial Title Immune Checkpoint Inhibitor Toxicity (I-CHECKIT): A Prospective Observational Study
Trial Status Open to Enrollment
Start Date 11/16/2021
Location hospitals
Trial Type Cancer - Adult Oncology
Specific Condition Cancer Control
Description This study examines how certain risk factors (such as age, gender, other medical conditions, and the type of immunotherapy used to treat the cancer) affect whether a patient with a malignant solid tumor will develop mild or serious side effects from the immunotherapy medications. Immunotherapy is the type of treatment that helps the body's immune system fight cancer. In the future, this information may help doctors make better decisions about cancer treatments.
Eligibility Criteria

Eligibility Criteria

  • Participants must be planning to receive ICI-based therapy for a solid tumor malignancy.
  • Participants must not have received chemotherapy, biologic, or targeted-therapy within 21 days prior to registration.
  • Participants must not be planning to receive ICI-based therapy in combination with chemotherapy or any other non-ICI therapy for treatment of their cancer.
  • Participants must be at least 18 years of age.
  • Participants must complete their history and physical examination within 28 days prior to registration.

Please contact Legacy Oncology Research for additional study inclusion/exclusion information.

IRB Number Central IRB
Notes Immune Checkpoint Inhibitor Toxicity Risk Prediction in Solid Tumors - Full Text View - ClinicalTrials.gov
Principal Investigator Onyekachi Ogbonna, MD
Contact Name Oncology Clinical Research
Contact Phone 503-413-8199
Contact Fax 503-413-6920
Contact E-Mail oncologyresearch@lhs.org